Affimed N.V., a clinical-stage immuno-oncology company, announced that an abstract on its phase 2 LuminICE-203 study involving the innate cell engager acimtamig in combination with AlloNK has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback